The global herpes market encompasses the development and distribution of antiviral medications aimed at treating both oral and genital herpes infections caused by the herpes simplex virus (HSV). These medications alleviate symptoms, reduce outbreak frequency, and suppress viral shedding, thereby mitigating transmission risk. Moreover, ongoing research in this market focuses on the development of vaccines to prevent herpes infections altogether, aiming to lessen the global burden of the disease and improve public health outcomes.
Global Herpes Market valued at USD 1.24 billion in 2023, is projected to reach 2.06 billion by 2031 and will grow at a CAGR of 6.6% during the forecast period of 2024-2031.
To know more, visit https://www.databridgemarketresearch.com/ar/reports/global-herpes-market
Below are the Top Herpes Companies with a Significant Market Share:
|
Rank
|
Company
|
Overview
|
Product Portfolio
|
Sales Geographical Coverage
|
Developments
|
|
1.
|
GSK plc.
|
As a leading pharmaceutical company, GSK is actively involved in the global herpes market through its development and marketing of antiviral medications such as valacyclovir (Valtrex) for both oral and genital herpes. It also invests in research for herpes vaccines, aiming to address the unmet medical needs in herpes prevention and treatment.
|
|
South America, Middle East and Africa, Asia-Pacific, and North America
|
In January 2021, GSK ranks 1st in the 2021 Access to Medicine Index with leading R&D pipeline for priority diseases. The ranking is based on progress companies are making in improving access to medicine in 106 low- and middle-income countries and in relation to 82 diseases, conditions and pathogens. This will increase the demand for the company’s products in the forecasted period.
|
|
2.
|
Viatris Inc.
|
Viatris, formed through the merger of Mylan and Upjohn (a division of Pfizer), participates in the herpes market by offering generic versions of antiviral medications such as acyclovir, which provide affordable treatment options for herpes patients worldwide, contributing to accessibility and affordability of herpes medications.
|
|
Europe, South America, Middle East and Africa, Asia-Pacific, and North America
|
In November 2019, Mylan N.V. announced the combination of the company with Upjohn, a division of Pfizer, the new company formed would be named as Viatris. The merger of both the company to develop a combined firm has expanded the company’s product portfolio leading to increased demand for its product in the market.
|
|
3.
|
Fresenius Kabi AG
|
Fresenius Kabi play a key role in the herpes market by manufacturing and distributing intravenous antiviral medications used in severe cases of herpes infection, such as acyclovir injections for herpes encephalitis or neonatal herpes.
|
|
Europe, Americas, Middle East and Africa, and Asia-Pacific
|
In April 2021, Fresenius Kabi in Haina was again recognized as Best Place to Work in the Dominican Republic and the Caribbean. The recognition increased the credibility of the company in the market and thus increased revenue generation.
|
|
4.
|
Pfizer Inc.
|
Pfizer, a global pharmaceutical giant, has a presence in the herpes market through its past ownership of Upjohn, which developed medications such as acyclovir (Zovirax) for herpes treatment. Its contributions to antiviral therapies have had a significant impact on herpes management.
|
|
Europe, South America, Middle East and Africa, Asia-Pacific, and North America
|
In November 2019, Pfizer, Inc. announced that its division named Upjohn is combined with Mylan N.V. and formed a new company named Viatris. This combination of the company's business division with Mylan N.V. has increased its product portfolio, leading to increased demand for its product in the market.
|
|
5.
|
Teva Pharmaceuticals USA, Inc.
|
Teva, a major generic drug manufacturer, contributes to the herpes market by producing generic versions of antiviral medications such as acyclovir and valacyclovir, offering cost-effective alternatives to brand-name drugs. Its broad portfolio and global reach make Teva an important player in providing access to herpes medications worldwide.
|
|
U.S.
|
|
Conclusion
The global herpes market, companies such as GSK plc., Viatris Inc., Fresenius Kabi AG, Pfizer Inc., and Teva Pharmaceuticals USA, Inc. play crucial roles in providing access to antiviral medications and advancing research for improved treatments and preventive measures. Their contributions alleviate symptoms and reduce transmission rates and address the socioeconomic aspects of healthcare by offering affordable generic alternatives. As research continues and innovative solutions emerge, these companies remain integral to combating the herpes virus and enhancing public health outcomes worldwide.
